China NMPA Inspection - Beijing Rimeng Biotechnology Co., Ltd. - December 31, 2020

An unannounced inspection of Beijing Rimeng Biotechnology Co., Ltd. was conducted by the National Medical Products Administration Food and Drug Inspection Center and the Beijing Municipal Drug Administration, with the notice released on December 31, 2020. The inspection identified several critical issues pertaining to the company's quality management systems.

Specifically, Beijing Rimeng Biotechnology Co., Ltd. was found to have inadequate implementation of its material supply management systems. Furthermore, deficiencies were noted in material and product management, particularly regarding the raw material procurement documentation systems, which were not properly followed. The inspection also revealed non-standard practices in production management, as evidenced by irregular batch production records. These findings indicate a lack of adherence to the established regulatory framework, specifically the "Key Points for Cosmetics Production License Inspection," which governs cosmetics manufacturing standards.

As a result of these violations, the Beijing Municipal Drug Administration has mandated that Beijing Rimeng Biotechnology Co., Ltd. undertake immediate corrective actions. The company is required to rectify all identified issues within a specified timeframe. Following the implementation of these corrective measures, the company must submit a comprehensive report detailing its compliance efforts to the Cosmetics Supervision Department of the National Medical Products Administration within two months of the directive. This action aims to ensure the company's operations meet the necessary quality and production standards for cosmetics manufacturing.